This inventor holds 16 USPTO granted patents. Top assignees: Takeda Chemical Industries, Inc., Takeda Chemical Industries, Co., Ltd.. Active years: 1988-2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Mishima, JP (1988 - 1995)
- Shimamoto, JP (1994 - 1995)
- Shimamoto-cho, JP (1996)
- Mishima-gun, JP (1996 - 1998)
- Osaka, JP (1995 - 2002)
Company Filing History:

Years Active: 1988-2002
Title: Kenji Okonogi: Innovator in Azole Compounds
Introduction
Kenji Okonogi is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of chemistry, particularly in the development of azole compounds. With a total of 16 patents to his name, Okonogi's work has had a substantial impact on antifungal treatments.
Latest Patents
One of Okonogi's latest patents focuses on azole compounds, their production, and their use. This patent describes a quaternized nitrogen-containing imidazol-1-yl or 1,2,4-triazol-1-yl compound. The innovation involves a substituent that can be eliminated in vivo, converting it into an antifungal azole compound. This compound boasts improved solubility in water, making it suitable for injection. Additionally, it has enhanced internal absorption and is expected to be effective in treating or preventing diseases.
Career Highlights
Throughout his career, Kenji Okonogi has worked with notable companies, including Takeda Chemical Industries, Inc. and Takeda Chemical Industries, Co., Ltd. His expertise in the field has led to numerous advancements in pharmaceutical chemistry.
Collaborations
Okonogi has collaborated with esteemed colleagues such as Katsumi Itoh and Akihiro Tasaka. These partnerships have fostered innovation and contributed to the success of his research endeavors.
Conclusion
Kenji Okonogi's work in azole compounds exemplifies the importance of innovation in the pharmaceutical industry. His contributions continue to influence the development of effective treatments for various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile